Why is it difficult to justify the use of a placebo control in a trial in which a "standard-of-care" therapy already exists? why is a placebo control easier to justify in trials in which there is no established "standard-of-care" therapy? should those participating in a clinical trial be notified of the possibility that they may be given a placebo?

Harold, a fifty-eight year old grocery store manager, had recently been waking up in the middle of the night with abdominal pain. this was happening several nights a week. he was also experiencing occasional discomfort in the middle of the afternoon. harold decided to schedule an appointment with his physician. the doctor listened as harold described his symptoms and then asked harold some questions. he noted that harold's appetite had suffered as a result of the pain he was experiencing and as a result of the fear that what he was eating may be responsible for the pain. otherwise, harold seemed fine. the doctor referred harold to a physician that specialized in internal medicine and had harold make an appointment for a procedure called an endoscopy. the endoscopy was performed at a hospital later that week. during the procedure, a long, thin tube was inserted into harold's mouth and directed into his digestive tract. the end of the tube was equipped with a light source and a small camera which allowed the doctor to observe the interior of harold's stomach. the endoscope was also equipped with a small claw-like structure that the doctor could use in order to obtain a small tissue sample from the lining of harold's stomach, if required. the endoscopy revealed that harold had a peptic ulcer. analysis of a tissue sample taken from the site showed that harold also had an infection that was caused by helicobacterpylori bacteria. the doctor who performed the endoscopy gave harold prescriptions for two different antibiotics and a medication that would decrease the secretion of stomach acid. the doctor also instructed harold to schedule an appointment for another endoscopy procedure in 6 months. 1. list the subjective findings in this case study. 2. what is an endoscopy? (2 points) what is a biopsy? 3. how was a biopsy performed on harold? 4. differentiate between gastric and duodenal ulcers by location. 5. what role does h. pylori play in the formation of peptic ulcers? 6. define occult and frank blood. (4 points) what is a guaiac test? 7. how can peptic ulcers cause bleeding? 8. why were antibiotics prescribed? 9. why would a medication that would decrease the secretion of stomach acid be beneficial?

Aperson has been born with a mutation that results in a deficiency in the production of mhc i by all of their cells. how might this deficiency affect a person immunologically?

Mr. wayne is a 38-year-old man with a significant history of elevated cholesterol levels. his father died at age 42 from a massive heart attack secondary to elevated cholesterol and triglycerides, and two of his older siblings are currently taking medications to lower their cholesterol levels. mr. wayne makes an appointment to discuss his risk for hypercholesterolemia. the nurse recognizes that mr. wayne is at risk for familial hypercholesterolemia because this is an autoomal dominant inherited condition. a. describe the pattern of autosomal dominant inheritance. b. mr. wayne asks what chance his children have of developing familial hypercholesterolemia. how should the nurse respond? c. explain the phenomenon of penetrance observed in autosomal dominant inheritance.